All targets for the benefit reassessment will be negotiated

with the NHIS

Negotiation on supply and quality control obligations by the 18th of next month

All six active ingredients-related companies that re-evaluated their benefit adequacy with the HIRA this year will meet at the negotiating table with the NHIS.

 

In particular, the components for which the benefit maintenance has been decided will also be negotiated with the NHIS.

 

Streptokinase and Streptodornase will negotiate the recovery according to the results of clinical re-evaluation, and 37 companies are subject to negotiation.

 

Some predict that it will not be easy to meet the 30-day deadline for negotiations.

 

According to the NHIS on the 18th, a negotiation order for drugs subject to this year's drug benefit adequacy evaluation will be issued from the Ministry of Health and Welfare on the 14th and will proceed with individual companies until the 18th of next month.

 

Except for Streptokinase and Streptodornase, which are negotiating the return, the rest of the items will be carried out by the generic management department of the drug management office of the industrial complex.

 

The contents of the negotiations are related to supply and quality management obligations, and if there is no problem with supply, there will be no problem in concluding the negotiations.

 

There is a possibility that the companies are not ready because the targets of this negotiation include Almagate, and Tiropramide, which have maintained salaries.

 

In response, the NHIS is also contacting individual companies that have sanctions that have been ordered to negotiate and maintained salaries to guide them that they are subject to negotiations.

 

Celltrion Pharmaceutical's Godex, which was the biggest concern for benefit reassessment, will also negotiate.

 

However, negotiations on separate drug prices are not expected to proceed as Celltrion Pharmaceutical has been recognized for its appropriateness by voluntarily cutting drug prices.

 

The problem is companies with Streptokinase and Streptodornase that have to go through negotiations with the Ministry of Drug Safety and Drug Administration Improvement in the industrial complex.

 

On the 6th, the HIRA decided to suspend the evaluation for one year only for items agreed on in the return negotiation according to the results of the clinical re-evaluation.

 

The companies can maintain their benefits only when they agree with the NHIS in negotiations.

 

It is known that there are 37 target companies alone.

 

Currently, the NHIS-related departments and pharmaceutical companies are working on strategies internally.

 

The NHIS official said, "We plan to reach an agreement, such as the timing and rate of recovery while listening to and coordinating the opinions of the target companies." This year's drugs subject to the re-evaluation of benefit adequacy were six-component drugs, including Streptokinase and Streptodornase, Eperisone HCl, Godex, Sodium Alginate, Almagate, and Tiropramide Hydrochloride.

 

Among them, Streptokinase and Streptodornase were conditional evaluation suspended, Eperisone HCl, and sodium Alginate were not recognized for some indicative benefit eligibility, and all other drugs were recognized for their benefit appropriateness.